We investigated a one-step immunometric CA 125 assay, which employs new anti-CA 125 antibodies as capture antibodies and OC125 antibodies for detection, for interference due to antibodies induced by repeated administration of F(ab') 2 fragments of the anti-CA 125 antibody OC125. Testing 33 samples, obtained from 13 patients treated with OC125 fragments, we found falsely high CA 125 concentrations only in samples with exceptionally high concentrations of both anti-idiotypic antibodies and non-specific human anti-mouse antibodies. In contrast, the recovery of added CA 125 was already diminished in the presence of low antiidiotypic antibody concentrations. Both interferences disappeared after removal of serum IgG. It was possible to eliminate the falsely high results, but not the reduction in recovery rate, by adding non-specific murine IgG. When the binding of the detector antibodies was performed in a separate incubation step, no reduction in recovery rate was observed. Our results suggest that non-specific human anti-mouse antibodies are responsible for falsely high results. The reduction in the recovery rate is obviously due to an inhibition of the binding of OC125 detector antibodies by anti-idiotypic antibodies. In patients receiving OC125 antibodies CA 125 can be measured using OC125 detector antibodies if a two-step assay is performed. An increase in CA 125 following OC125 infusion should be confirmed after the addition of non-specific murine IgG.
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In the present study we investigated an immunometric test for CA 125 that involves a newly developed anti-CA 125 antibody on the solid phase and I25 I-labelled OC125 antibodies for detection, for interferences due to antibodies formed after treatment with OC125 fragments. Furthermore, the mechanisms of the observed interferences were investigated.
OC125 antibodies are used as both the immobilized and the labelled antibodies, anti-idiotypic antibodies directed against idiotypes of the OC125 can simulate the presence of antigen by cross-linking capture and detector antibodies (9, 10 l-labelled detector antibodies. According to the normal test protocol proposed by the manufacturers, the binding of both antibodies takes place simultaneously during one incubation step: 0.1 ml of the samples were incubated together with 0.3 ml of radioiodinated OC125 antibodies in test tubes coated with anti-CA 125 capture antibodies (20 h, room temperature). After the incubation the tubes were washed and the bound radioactivity was measured.
In some cases we performed a modified two-step test in order to exclude the possibility that serum components not bound to the solid phase might interfere with the binding of detector antibodies: in the first step 0.1 ml of sample were incubated (20 h, room temperature) with the immobilized capture antibodies together with 0.3 ml of zero standard (provided with the ELSA-CA 125 II test kit) supplemented with 0.1 g/1 of nonspecific murine IgG (Calbiochem Novabiochem, Bad Soden, Germany). After the incubation the tubes were washed to remove all serum components not bound to the solid phase. In the second step 0.3 ml of radioiodinated OC125 antibodies were incubated (20 h, room temperature) with 0.1 ml of zero standard. After a further wash the bound radioactivity was measured. If not otherwise indicated the test was performed according to the normal test protocol.
Recovery of CA 125
In order to identify inhibitory agents in serum samples we determined the recovery of a known amount of CA 125 added to the native serum: 0.01 ml of a serum pool from an ovarian cancer patient with a CA 125 concentration of 5000 χ ΙΟ 3 arb. U/l were added to 0.24 ml of sample and the resulting CA 125 concentration was measured with the ELSA-CA 125 II. Recovery was expressed as fraction of the amount added.
Determination of anti-idiotypic antibodies
Anti-idiotypic antibodies were determined with the Abbott CA 125 El A monoclonal. Since in this immunometric test the Determination of non-specific human anti-mouse antibodies Non-specific anti-mouse antibodies (anti-iso/allotypic antibodies) were determined with the ImrmiSTRIP HAMA-EIA (Irnmunomedics Inc., Newark, NJ) as previously described (9) .
Removal of interfering IgG from serum samples
Interfering IgG were removed by affinity chromatography on Protein G-Sepharose (Pharmacia, Freiburg, Germany). We applied 1 ml of serum sample diluted 2-fold with phosphate buffer (0.2 mol sodium phosphate and 10 g bovine serum albumin per litre, pH 7.0) to the 2,5 ml column equilibrated with phosphate buffer. After a 5-min incubation at room temperature, the column was washed with 8 ml of phosphate buffer to elute the unadsorbed fraction. The complete wash fraction was frozen immediately at -^80°C and subsequently lyophilized. At the time of further use the IgG-free samples were reconstituted with 1 ml of distilled water. The absorbed IgG fraction was eluted with 4 ml of elution buffer (1 mol/1 glycine HC1 buffer, pH 2.8), after a further wash with 5 ml of phosphate buffer. The eluate was neutralized immediately with 0.4 ml of neutralizing buffer (1 mol/1 sodium phosphate, pH 8.0), frozen at -80 °C and lyophilized. At the time of further use the IgG fractions were reconstituted with 1 ml of distilled water.
Blocking of non-specific human anti-mouse antibodies
To block anti-iso/allotypic antibodies non-specific murine IgG (Calbiochem Novabiochem, Bad Soden, Germany) were added to the native serum samples. Murine IgG solution (0.01 ml) (16.6 g/1) was added to 0.24 ml of sample.
Results

Falsely high CA 125 values
In 33 serum samples, obtained from 13 patients after treatment with OC125 fragments, we determined the apparent CA 125 concentration with the ELSA-CA 125 II. While the real CA 125 concentrations determined after removal of interfering IgG iri all samples were lower than 30 χ ΙΟ 3 arb. U/l, in 7 native sanu pies, with elevated concentrations of both anti-idiotypic antibodies (8 400 -1 552 000 χ l O 3 arb. U/l) and non-specific human anti-mouse antibodies (965^-18 800 μg/l), we measured falsely high CA 125 values up to 126 χ 10 3 arb. U/l. with anti-idiotypic antibody concentrations exceeding 5000 χ 10 3 arb. U/l less than 20% of the added CA 125 was recovered. When binding of the detector antibodies was performed in a separate incubation step according to the modified test protocol, the CA 125 recovery was quite good. Further, from samples with anti-idiotypic antibody concentrations exceeding 5000 χ 10 3 arb. U/l the CA 125 was recovered completely.
In 5 samples with reduced recovery rates we removed serum IgG by means of chromatography on protein G sepharose. After IgG removal, the added CA 125 was recovered nearly completely from all samples, whereas from the IgG-containing elution fraction of the protein G column the recovery was diminished ( fig. 2) . Non-specific murine IgG were added to another 5 samples with reduced recovery rates to block putative activity of non-specific human anti-mouse antibodies. The recovery rates were not influenced by the addition of (0.66 g/1) murine IgG (tab. 2). In a previous study we observed similar effects with two other immunometric assays for CA 125 which also employ no OC125 antibodies on the solid phase (11) . We assume that such interference may be due-to non-specific human anti-mouse antibodies formed after treatmerirwith OC125 fragments, which simulate the presence of antigen by crosslinking capture and detector antibodies. Interference by non-specific human anti-mouse antibodies has been reported for several immunometric assays (13 -16) . Thus, as with the ELSA-CA 125 II we used in this study, most imrnunoassays include non-specific murine immunoglobulins to block the activity of non-specific human antimouse antibodies (14, 15, 17) . However, as demonstrated by Boscato & Stuart (18) , in samples with very high concentrations of non-specific human antimouse antibodies the amount of murine immunoglobulin added to an assay system may not always be enough to prevent interference. Falsely high results in the ELSA-CA 125 II may be due to non-specific human anti-mouse antibodies not further blocked by murine immunoglobulins. This hypothesis is supported by the fact that it was possible to block interference by the addition of murine IgG.
A more prominent interference observed with the ELSA-CA 125 II is the reduction of assay response, which is evident in recovery studies. The negative correlation between the extent of recovery and the concentration of anti-idiotypic antibodies and the fact that the inhibitory agents were absorbed by protein G and were recovered in the IgG-containing eluate, suggest that the responsible agents were human serum IgG formed together with the anti-idiotypic antibodies after treatment with OC125 fragments. Reduction of assay response can be produced by high concentrations of non-specific human antirinouse antibodies, presumably due to the inhibition of antigen-binding to reagent antibodies (18, 19) . However, the effect observed with the ELSA-CA 125II cannot be ascribed to non-specific human anti-mouse antibodies because it could not be blocked by murine IgG. The fact that no interference occurred in the modified two-step test version indicates that interfering agents react with the OC125 detector antibodies used in the test studied. Thus, the results support the hypothesis that the reduction of assay response is due to anti-idiotypic antibodies that mask the OC125 detector antibodies and prevent the binding of CA 125. This is also in accordance with the fact that we observed no reduction of assay results in the presence of aiiti-idiotypic antibodies with another two-step immunometric CA 125 assay using OC125 antibodies for detection (12) .
The use of test kits involving no OC125 antibodies as capture antibodies cannot completely eliminate interference by antibodies newly formed after the treatment with OC125 fragments. Even with these tests falsely high results can occur, due presumably to high concentrations of non-specific human anti-mouse antibodies. Thus, increased CA 125 values following OC125 application should be confirmed after addition of non-specific murine IgG. To avoid falsely low results, assays involving OC125 antibodies for detection should be performed in a two-step protocol.
